ImmuCell Corporation plans a conference call on January 9, 2026, to discuss strategic changes and fourth-quarter sales results.
Quiver AI Summary
ImmuCell Corporation, an animal health company focused on improving cattle health and productivity, has scheduled a conference call for January 9, 2026, at 9:00 AM ET to discuss its strategic shift towards the First Defense® product line and away from Re-Tain®. This follows a previous announcement made on December 24, 2025. During the call, the company will also share its unaudited topline sales results for the fourth quarter and full year ending December 31, 2025, with results being released after market close on January 8, 2026. Interested participants can join the call by dialing the provided numbers. Additionally, ImmuCell plans to release its full unaudited financial results on February 25, 2026, followed by another conference call on February 26, 2026. The company's mission is to create effective products that enhance cattle health, including its key offering First Defense®, which provides immunity to newborn calves.
Potential Positives
- The Company will announce its unaudited topline sales results for the fourth quarter and full year ended December 31, 2025, which could provide insights into its financial performance and market demand.
- ImmuCell is strategically shifting focus towards the First Defense® product line, indicating a potential growth opportunity and alignment with market needs.
- The conference call scheduled for January 9, 2026, allows for investor engagement and transparency regarding the company's new strategic direction.
Potential Negatives
- The press release indicates a strategic shift away from the Re-Tain® product line, which could signify potential weaknesses or declining performance in that segment of their business.
- ImmuCell will be providing unaudited topline sales results, which may raise concerns regarding the reliability of the data and future financial performance.
- The timing of the conference calls and financial disclosures suggests that the company may need to address investor concerns regarding transparency and significant changes in business strategy.
FAQ
When is ImmuCell's conference call scheduled?
ImmuCell's conference call is scheduled for Friday, January 9, 2026, at 9:00 AM ET.
How can I join the conference call?
You can join by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international).
What will be discussed during the conference call?
The call will discuss the strategic focus on First Defense® and the 2025 unaudited topline sales results.
When are the unaudited sales results released?
The unaudited topline sales results will be released after the market closes on January 8, 2026.
What is ImmuCell's main product line?
ImmuCell focuses on the First Defense® product line, providing Immediate Immunity™ to newborn dairy and beef calves.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICCC Insider Trading Activity
$ICCC insiders have traded $ICCC stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICCC stock by insiders over the last 6 months:
- BOEKHORST PAUL FRANCIS OLIVIER TE (President and CEO) has made 3 purchases buying 9,785 shares for an estimated $48,588 and 0 sales.
- DAVID SCOTT TOMSCHE has made 2 purchases buying 3,266 shares for an estimated $15,554 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ICCC Revenue
$ICCC had revenues of $5.5M in Q3 2025. This is a decrease of -8.41% from the same period in the prior year.
You can track ICCC financials on Quiver Quantitative's ICCC stock page.
$ICCC Hedge Fund Activity
We have seen 8 institutional investors add shares of $ICCC stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STEADTRUST LLC added 31,700 shares (+inf%) to their portfolio in Q3 2025, for an estimated $198,125
- CITADEL ADVISORS LLC removed 19,482 shares (-47.6%) from their portfolio in Q3 2025, for an estimated $121,762
- PROSPERITY PLANNING, INC. removed 16,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $100,000
- DIMENSIONAL FUND ADVISORS LP removed 7,648 shares (-10.9%) from their portfolio in Q3 2025, for an estimated $47,800
- DAUNTLESS INVESTMENT GROUP, LLC removed 7,573 shares (-8.0%) from their portfolio in Q3 2025, for an estimated $47,331
- UBS GROUP AG removed 7,391 shares (-88.1%) from their portfolio in Q3 2025, for an estimated $46,193
- STRATEGIC FINANCIAL SERVICES, INC. added 6,000 shares (+19.4%) to their portfolio in Q3 2025, for an estimated $37,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET.
The Company first announced a strategic change in focus in favor of the First Defense ® product line and away from Re-Tain ® on December 24, 2025. The Company will also discuss its unaudited topline sales results for the fourth quarter and full year ended December 31, 2025, which will be announced after the market closes on Thursday, January 8, 2026.
Conference Calls:
The Company is planning to host a conference call on Friday, January 9, 2026 at 9:00 AM ET to discuss its strategic shift to
First Defense
®
and away from
Re-Tain
®
as well as its 2025 unaudited topline sales results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until January 16, 2026, at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #6043808.
The Company is planning to release its full, unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, February 25, 2026 and is planning to host a conference call on Thursday, February 26, 2026 at 9:00 AM ET to discuss these results. Interested parties can access that conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 5, 2026, at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2017737.
About ImmuCell:
ImmuCell Corporation's (
Nasdaq: ICCC
) purpose is to create scientifically proven and practical products that improve cattle health and productivity. ImmuCell manufactures and markets
First Defense
®
, providing
Immediate Immunity
™ to newborn dairy and beef calves. Press releases and other information about the Company are available at:
http://www.immucell.com
.
| Contacts: |
Olivier te Boekhorst, President and CEO
Timothy C. Fiori, Chief Financial Officer ImmuCell Corporation [email protected] |
|
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC [email protected] |
